Business Wire

Elliott Statement on Sampo

11.11.2020 10:00:00 EET | Business Wire | Press release

Share

Elliott Advisors (UK) Limited (“Elliott” or “we”), which advises funds that as at the date of this release collectively hold investments equivalent to more than 3% of the share capital of Sampo Oyj (“Sampo” or the “Company”), welcomes Sampo’s decision to begin the disposal of its investment in Nordea Bank Abp (“Nordea”). Elliott believes this announcement will help to highlight the value of Sampo’s insurance assets, particularly IF P&C, and marks a positive first step towards Sampo making the rapid structural simplifications necessary to re-establish its reputation among shareholders. Elliott believes that a value-creation plan that transforms Sampo into a pure-play insurance company would provide much needed focus and strategic clarity for Sampo, while unlocking in excess of EUR 7 billion in value for shareholders.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201110006320/en/

Elliott’s investment in Sampo reflects our conviction in the intrinsic value of IF P&C, which represents the majority of Sampo’s value. In our view, Sampo’s management team has built the best underwriter in the most attractive P&C insurance market in Europe, a remarkable achievement that reflects the track record of Sampo’s current CEO and CFO, both of whom led IF P&C for the past two decades. As a result of its sustainable competitive advantages, IF P&C stands head and shoulders above its insurance peers in terms of COR outperformance and stability, along with attractive growth opportunities, all of which have enabled the company to generate stable, growing dividends. In addition to IF P&C, Sampo’s portfolio of insurance companies includes stakes in Topdanmark AS, Mandatum Life Insurance Co Ltd and the recently announced acquisition of Hastings Group Holdings plc. Outside of insurance, Sampo owns minority stakes in several private equity investments and a significant stake in Nordea, which has materially outperformed the broader banking market over the past decade.

However, Sampo’s structural complexity and a lack of clarity in its longer-term strategic narrative have contributed to a profound and persistent disconnect between the Company’s intrinsic strengths and its market valuation over the past two years. This significant share price underperformance has not been operationally driven, but rather the result of growing divergence between the performance of the wider insurance and banking sectors. Sampo’s share price has suffered due to the weak share price performance of Nordea, which has damaged sentiment in Sampo and has caused a substantial de-rating of Sampo’s insurance assets, which have seen their P/E multiple vs. peers reduce by ~8x since 2017.

Elliott believes that reconstructing Sampo’s equity story now, through full-scale structural simplification, is necessary to allow the market to appropriately value the Company’s industry-leading insurance assets. This pathway would entail the full separation of Sampo’s investment in Nordea and divestment of Sampo’s various private equity investments. A more coherent corporate structure would allow Sampo’s talented management team to provide more focused stewardship of its different assets and alleviate investor uncertainty surrounding Sampo’s strategy. Elliott believes these sensible measures could create in excess of EUR 7 billion of value, thereby restoring market confidence and reinforcing management’s reputation for delivering value-creating outcomes. In Elliott’s view, yesterday’s announcement is a first step on the path to creating more than 35% upside for Sampo shareholders, underscoring the importance of executing these actions expeditiously.

We look forward to Sampo’s continued transformation and to its February 2021 Capital Markets Day. To provide further details on how Sampo can build upon yesterday’s announcement, Elliott is enclosing a presentation with this press release.

About Elliott

Elliott Management Corporation manages approximately $41 billion of assets. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds of its kind under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Management Corporation.

Disclaimer

Elliott intends to reviews its investments in the company on a continuing basis and depending upon various factors, including without limitation, the company’s financial position and strategic direction, the outcome of any discussions with the company, overall market conditions, other investment opportunities available to Elliott Management, and the availability of company securities at prices that would make the purchase or sale of company securities desirable, Elliott may from time to time (in the open market or in private transactions, including since the inception of Elliott position) buy, sell, cover, hedge or otherwise change the form or substance of any of its investments (including company securities) to any degree in any manner permitted by law and expressly disclaims any obligation to notify others of any such changes. Elliott also reserves the right to take any actions with respect to its investments in the company as it may deem appropriate.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

London
Sarah Rajani CFA
Elliott Advisors (UK) Limited
T: +44 (0)20 3009 1475
srajani@elliottadvisors.co.uk

Finland
Mikael Jungner
Kreab
T: +35 850 554 1615
mikael.jungner@kreab.com

Sweden
Christina Rinman
Diplomat Communications
M: +46 709 711 213
christina.rinman@diplomatcom.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros Announces Publication of Phase 2 RAINBOW Study Data for Nizubaglustat in Molecular Genetics and Metabolism Journal5.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced the publication of clinical data from its Phase 2 (RAINBOW) study in the peer reviewed journal, Molecular Genetics & Metabolism. The published manuscript reports efficacy, safety, pharmacokinetic and pharmacodynamic data which evaluated nizubaglustat in patients with genetically confirmed GM2 gangliosidosis and NPC. As previously stated in the topline results announcement in July 2024, the RAINBOW study met its primary objective of demonstrating that nizubaglustat was safe and well tolerated. The study also showed encouraging signs of clinical efficacy, reducing disease progression and seizure burden in patients treated with nizubaglustat. “The publication of the RAINBOW data in a peer-reviewed journal represents an important milestone for Azafaros and for the broader lysosomal disease community,” said Stefano Portolano,

K-Startup Grand Challenge 2026: Korea's Full-Cycle Launchpad for Global Startups5.6.2026 04:00:00 EEST | Press release

South Korea’s Ministry of SMEs and Startups (MSS) has opened applications for the K-Startup Grand Challenge (KSGC), the country’s premier government-backed acceleration program for international startups targeting Korea and Asia. Since 2016, KSGC has attracted 21,537 applicants from more than 100 countries, among the world's most recognized inbound programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604794426/en/ South Korea’s Ministry of SMEs and Startups (MSS) has opened applications for K-Startup Grand Challenge 2026, a government-backed global startup acceleration program providing end-to-end support for international startups (Image: KSGC) A Full-Cycle Acceleration Journey Unlike conventional programs that focus on a single moment of market entry, KSGC 2026 guides startups from market entry to scale up in Korea - offered in a hybrid format - online or in person - with Demo Day held in Korea. The program runs Jul

Empire State Building Observation Deck Celebrates Soccer with World’s Most Iconic Soccer Jersey Exhibit, Custom ESB Jerseys, Player Visits, Lightings, and More5.6.2026 00:46:00 EEST | Press release

The Empire State Building Observation Deck (ESB) – the #1 Attraction in the United States – today announced further 2026 programming for soccer fans in New York City with the world’s most iconic jersey collection from the Classic Football Shirts (CFS) vault, a limited-edition ESB x CFS jersey, official merch giveaways, and special lightings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604370013/en/ Empire State Building Observation Deck Celebrates Soccer with World’s Most Iconic Soccer Jersey Exhibit, Custom ESB Jerseys, Player Visits, Lightings, and More “As the world descends upon New York City for this anticipated global soccer event, fans can visit the Empire State Building Observation Deck for Manhattan’s best skyline views and a one-of-a-kind soccer exhibit,” said Dan Rogoski, observatory general manager. “International and American soccer fans can extend the celebration off the pitch at the #1 Attraction in the

Vycellix to Provide Universal Cell Cancer Therapy Progress Reports at Upcoming Investor & Partnering Meetings4.6.2026 21:15:00 EEST | Press release

Vycellix, Inc., a biotechnology company developing next-generation allogeneic natural killer (NK) cell-based therapies designed to overcome the risk of immune rejection and redefine functional persistence with durability, today announced the Company will attend a series of upcoming investor and partnering meetings to share progress reports on the Company’s universal cell therapy platforms and product candidates targeting multiple myeloma, acute myeloid leukemia and urothelial cancers. Vycellix is attending: June 8-9: U.S. Department of Commerce Certified Trade Mission to Norway in Oslo June 11-14: European Hematology Association (EHA) 2026 Congress in Stockholm June 22-25: BIO International Convention in San Diego (Florida Pavilion, Booth# 1319) To request a meeting with Vycellix at any of these events, please contact Doug Calder at dcalder@vycellix.com. Vycellix recently announced the successful completion of pre-clinical development for its universal cell engineering platform (VY-UC)

Sodali & Co Appoints Fabio Bianconi as Head of Italy4.6.2026 20:15:00 EEST | Press release

Sodali & Co, the leading global capital markets-centric stakeholder advisory firm, today announced the appointment of Fabio Bianconi as Head of Italy, effective immediately. Fabio succeeds Andrea Di Segni, who will transition into a new role as Senior Relationship Advisor, where he will continue to support key client relationships and strategic initiatives across the firm. Fabio brings deep experience, strong client relationships, and a track record advising on complex mandates in the Italian market. He will lead Sodali’s continued growth and development in Italy, building on the firm’s established position in the region. Aneliya Crawford, Chief Partnerships Officer & Global Head of Shareholder Advisory of Sodali & Co, said: “Andrea has played a central role in the evolution of Sodali over more than two decades, helping establish the firm as a trusted global advisor in corporate governance and shareholder engagement. He built our Italian business into a leader in the market, as reflect

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye